LDH is an adverse prognostic factor independent of ISS in transplant‐eligible myeloma patients receiving bortezomib‐based induction regimens

Publisher： John Wiley & Sons Inc

E-ISSN： 1600-0609|94|4|330-335

ISSN： 0902-4441

Source： EUROPEAN JOURNAL OF HAEMATOLOGY, Vol.94, Iss.4, 2015-04, pp. : 330-335

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bortezomib‐containing induction regimens in transplant‐eligible myeloma patients

By  

CANCER, Vol. 119, Iss. 23, 2013-12 ,pp. : 4119-4128

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bortezomib Administered Subcutaneously Is Well Tolerated in Bortezomib-Based Combination Regimens Used in Patients with Multiple Myeloma

By  

Oncology, Vol. 85, Iss. 4, 2013-09 ,pp. : 223-227

Karger

Access to resources Recommend Favorite

Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib‐based treatment regimens

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 170, Iss. 1, 2015-07 ,pp. : 66-79

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bortezomib, Thalidomide, and Dexamethasone (VTD) Induction Results in Better Overall Survival than Adriamycin, Thalidomide, and Dexamethasone (ATD) Induction in Previously Untreated Myeloma Patients Eligible for Transplants

By  

Acta Haematologica, Vol. 137, Iss. 4, 2017-05 ,pp. : 207-208

Karger

Access to resources Recommend Favorite

Bortezomib‐based therapy combined with high cut‐off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 7, 2015-07 ,pp. : 647-652

John Wiley & Sons Inc

Access to resources Recommend Favorite